MDL-29951

SKU: orb1307204

Description

MDL-29951 is a selective glycine-site antagonist of the NMDA receptor. It is a valuable research tool for investigating glutamatergic neurotransmission in models of neurological disorders, applicable in both in vitro binding assays and in vivo studies.

Research Area

Immunology & Inflammation, Neuroscience

Key Properties

• CAS Number: 130798-51-5
• MW: 302.11
• Purity: >98%
• Formula: C₁₂H₉Cl₂NO₄
• SMILES: OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O
• Target: GPCR
• Solubility: Soluble in DMSO (up to 15 mg/ml with warming) or in Ethanol (up to 10 mg/ml).

Bioactivity

• Target IC50:
  NMDA:0.14 μM
• In Vitro:
  MDL 100,748 and MDL 29,951 are approximately 2000-fold selective for the glycine binding site relative to the glutamate recognition sites. MDL-29951 is found to inhibit the human F16Bpase under these conditions (IC50=2.5 μM). MDL-29951 inhibits the human liver (IC50=2.5 μM), porcine kidney (IC50=1.0 μM), and rabbit liver (IC50=0.21 μM) isoforms of the enzyme, but is significantly less potent against the rat liver isoform (IC50=11 μM). The MDL29951-activated receptor exhibits other activities associated with GPCR-mediated signaling, including G protein-dependent activation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and recruitment of β-arrestin. As with recombinant cell systems, MDL29951 promotes Ca2+ signaling responses and inhibition of cyclic adenosine monophosphate (cAMP) accumulation in rat oligodendrocyte precursor cells during the period of peak GPR17 abundance. Effects of MDL29951 are markedly reduced in cells with low GPR17 abundance and are blocked by pranlukast.

Storage & Handling

• Storage: RT
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Inhibitor, Ionotropic glutamate receptors, NMDA receptor, MDL 29951, MDL29951, MDL-29951, iGluR

Compound Identifiers

PubChem CID

446916